Axon Enterprise (NASDAQ:AXON) Director Jeri Williams Sells 100 Shares

Axon Enterprise, Inc (NASDAQ:AXON) Director Jeri Williams sold 100 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $550.63, for a total transaction of $55,063.00. Following the transaction, the director owned 1,316 shares of the company’s stock, valued at $724,629.08. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jeri Williams also recently made the following trade(s):

• On Thursday, September 11th, Jeri Williams sold 100 shares of Axon Enterprise stock. The stock was sold at an average price of $752.54, for a total value of $75,254.00.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $553.12 on Tuesday. The firm has a market capitalization of $43.65 billion, a P/E ratio of 175.04, a PEG ratio of 126.54 and a beta of 1.40. The stock has a 50-day simple moving average of $636.04 and a two-hundred day simple moving average of $718.82. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm’s revenue was up 30.6% on a year-over-year basis. During the same period last year, the business earned $1.45 earnings per share. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group cut their target price on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday, September 24th. Barclays lowered their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Finally, Piper Sandler lowered their price target on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $815.00.

Institutional Investors Weigh In On Axon Enterprise

Several institutional investors have recently bought and sold shares of the company. TCI Wealth Advisors Inc. acquired a new stake in shares of Axon Enterprise in the 2nd quarter valued at about $214,000. Wealthedge Investment Advisors LLC increased its position in Axon Enterprise by 180.7% during the second quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after buying an additional 775 shares during the period. Jaffetilchin Investment Partners LLC lifted its stake in Axon Enterprise by 11.7% in the second quarter. Jaffetilchin Investment Partners LLC now owns 5,938 shares of the biotechnology company’s stock valued at $4,916,000 after buying an additional 624 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Axon Enterprise by 3.5% in the second quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock valued at $7,399,515,000 after acquiring an additional 305,252 shares during the period. Finally, Duncker Streett & Co. Inc. boosted its holdings in shares of Axon Enterprise by 3.2% in the second quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock valued at $12,006,000 after acquiring an additional 448 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.